Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment

Predictive biomarkers of survival in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab treatment

Abstract Background Since atezolizumab plus bevacizumab (ATE+BEV) regimen for patients with unresectable hepatocellular carcinoma (HCC) was released quite recently, real‐world data are lacking. We evaluated efficacy, safety, and predictive biomarkers for survival in patients receiving ATE+BEV. Metho...

Full description

Bibliographic Details
Main Authors: Young Eun Chon, Jaekyung Cheon, Hyeyeong Kim, Beodeul Kang, Yeonjung Ha, Do young Kim, Seong Gyu Hwang, Hong Jae Chon, Beom Kyung Kim
Format: Article
Language:English
Published: Wiley 2023-02-01
Series:Cancer Medicine
Subjects:
atezolizumab
bevacizumab
hepatocellular carcinoma
neutrophil to lymphocyte ratio
des‐gamma‐carboxy prothrombin
Online Access:https://doi.org/10.1002/cam4.5161

Internet

https://doi.org/10.1002/cam4.5161

Similar Items